Table 3. Phase II and III clinical trials ongoing on anti-androgen drugs in triple negative breast cancer patients.
| Treatment | Other treatments | Status/key achievement | Identifier |
|---|---|---|---|
| Bicalutamide | Physician's choice, bicalutamide | Phase III, R | NCT03055312 |
| Physician's choice, bicalutamide | Phase II, U | NCT02353988 | |
| None | Phase II, T (slow enrolment of patients) | NCT02348281 | |
| Enzalutamide | Paclitaxel | Phase IIb, R | NCT02689427 |
| None | Phase II, ANR | NCT01889238 | |
| None | Phase II, ANR | NCT02750358 | |
| Enobosarm | Pembrolizumab | Phase II, R | NCT02971761 |
| None | Phase II, T (lack of efficacy) | NCT02368691 | |
| Seviteronel | None | Phase II, C | NCT02130700 |
| CR1447 | None | Phase II, ANR | NCT02067741 |
| Darolutamide | Capecitabine | Phase II, R | NCT03383679 |
| Orteronel | None | Phase II, R | NCT01990209 |
R = recruiting; U = unknown; T =terminated; ANR = active, not recruiting; C = completed.